Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Aspirin-a-day advice unheeded by those who need it

15.11.2005


A daily dose of aspirin is an inexpensive, proven strategy for reducing the likelihood of heart disease among those most at risk for such disorders, yet a new study from the Stanford University School of Medicine shows that aspirin therapy is being used by fewer than one-third of the U.S. outpatients who would benefit from it.



Instead, the research found, many doctors are opting to prescribe the more expensive, heavily marketed statin drugs, which are no more effective than aspirin in preventing heart disease.

"What really concerns us is the degree of aspirin underutilization among patients who have already had a heart attack or a stroke because this is the group for which there is conclusive clinical evidence that aspirin reduces the risk for cardiovascular disease," said Jun Ma, MD, PhD, research associate at the Stanford Prevention Research Center and senior author of the study that appears in the November issue of the Public Library of Science-Medicine.


Of those with the highest risk for cardiovascular disease, the study showed that only 33 percent of their outpatient visits were associated with aspirin therapy in 2003. That’s an increase from the 1993 rate of 22 percent, but Ma said the gain is minimal considering the abundant proof of aspirin’s benefits for such patients.

And although aspirin use remains low, the study found that U.S. physicians are increasingly prioritizing a class of drugs known as statins as the primary drug strategy for preventing heart disease. Statins, while as effective as aspirin in preventing heart attacks, cost substantially more. The researchers speculate that the heavy marketing of statins in the United States is spurring patients and doctors toward these newer - although not necessarily better - medications.

"Our concern is that physicians are failing to use the full range of strategies available to reduce patients’ risk of heart disease and stroke," said Randall Stafford, MD, PhD, associate professor of medicine at the Stanford Prevention Research Center and the first author of the study.

Cardiovascular disease remains the leading cause of death in the United States for both men and women. The American Heart Association estimates that the various types of cardiovascular disease, including heart attack and stroke, affect more than 70 million Americans.

Aspirin therapy is one way for patients diagnosed with a significant risk for heart disease to lower that risk. Aspirin reduces the clotting action of the blood’s platelets, thereby lowering the risk of heart attack, stroke and other diseases that can occur when the blood vessels are blocked by clots. In several clinical trials, daily doses of between 75 and 325 milligrams of aspirin cut the risk of cardiovascular events by 15 to 40 percent. However, aspirin can cause gastrointestinal bleeding in up to 4.5 percent of patients; physicians and patients must weigh that risk against aspirin’s benefits before deciding whether to use it.

For several years, clinical guidelines have recommended aspirin therapy for patients with a significant risk of heart disease. Ma and Stafford said their study is the first to examine how aspirin use varies among U.S. outpatients according to their heart-disease risk.

The researchers used two national databases that tracked outpatient visits to hospitals and physician offices between 1993 and 2003, and then assessed the reported use of aspirin therapy associated with those visits. Patients were categorized according to their risk of cardiovascular disease. High-risk patients were those who had been diagnosed with heart disease or had experienced a heart attack or stroke. Intermediate-risk patients were divided into two groups: one for those who had diabetes and additional risk factors for heart disease (such as high blood pressure, high cholesterol and smoking); and the other for non-diabetic adults with at least two risk factors for heart disease. All other patients were placed in the low-risk category.

While less than a third of the high-risk patient visits were associated with aspirin therapy, the 2003 rates were even lower for those in the intermediate groups: 12 percent of the diabetic group and 16 percent for the non-diabetics.

Ma and Stafford acknowledged that measuring aspirin usage is difficult because doctors don’t always document the over-the-counter medications their patients take. However, based on previous studies that found low rates of aspirin use, the researchers said they don’t believe such under-reporting would account for the huge gap between the clinical recommendations and what they found in the new study.

One finding that intrigued the researchers is the growing popularity of statins, which help reduce the amount of LDL or "bad" cholesterol in the blood. Statins and aspirin have similar overall rates of effectiveness in reducing cardiovascular risk, but they vary significantly in cost. A daily dose of the most frequently prescribed statin medication costs around $2 while a daily dose of aspirin costs mere pennies.

Susan Ipaktchian | EurekAlert!
Further information:
http://www.stanford.edu
http://mednews.stanford.edu

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>